Department of Cardiovascular Sciences, University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK; Leicester Vascular Institute, University Hospitals of Leicester, Glenfield Hospital, Leicester, UK; British Heart Foundation, Clinical Research Training Fellow, Leicester, UK.
Leicester Vascular Institute, University Hospitals of Leicester, Glenfield Hospital, Leicester, UK.
Eur J Vasc Endovasc Surg. 2024 Mar;67(3):468-479. doi: 10.1016/j.ejvs.2023.11.007. Epub 2023 Nov 4.
Biomimetic stents are peripheral infrainguinal self expanding stents that mimic the anatomy of the vasculature and artery movement. They are indicated for use in infrainguinal arteries. This research aimed to synthesise all current evidence on the use of biomimetic stents as adjuncts for endovascular treatment of infrainguinal peripheral arterial disease (PAD), helping to guide clinical decision making.
MEDLINE, Embase, CINAHL and Cochrane databases.
Random effects meta-analysis following PRISMA guidelines (PROSPERO registration CRD42022385256). Study quality was assessed using the Joanna Briggs Institute critical appraisal tools checklist, and certainty assessment through the Grading of Recommendations, Assessment, Development and Evaluation (GRADE). Endpoints included primary patency, target lesion revascularisation, stent fracture, secondary patency, and Death at one year.
In total, 37 studies were included in the meta-analysis (33 cohort studies, two case series, and two randomised controlled trials [RCTs]), representing 4 480 participants. Of these, 34 studies included data on the Supera (81.5% of participants) and three studies reported data on the BioMimics 3D (18.5% of participants) stents. The pooled primary patency rate of 33 studies at one year follow up was 81.4% (95% confidence interval [CI] 78.7 - 83.9%), and the pooled target lesion revascularisation rate of 18 studies at one year was 12.2% (95% CI 9.6 - 15.0%). The certainty of evidence outcome rating as qualified by GRADE was very low for both. Only one study reported a positive stent fracture rate at one year follow up of 0.4% with a certainty of evidence outcome of low.
Using biomimetic stents for infrainguinal PAD may be associated with acceptable one year primary patency and target lesion revascularisation rates, with a near negligible one year stent fracture rate. Their use should be considered in those presenting with infrainguinal PAD undergoing endovascular revascularisation. A RCT is necessary to determine their clinical and cost effectiveness.
仿生支架是一种外周下肢自扩张支架,模仿血管解剖结构和动脉运动。它们适用于下肢动脉。本研究旨在综合所有关于仿生支架作为下肢外周动脉疾病(PAD)血管内治疗辅助手段的现有证据,以帮助指导临床决策。
MEDLINE、Embase、CINAHL 和 Cochrane 数据库。
按照 PRISMA 指南进行随机效应荟萃分析(PROSPERO 注册 CRD42022385256)。使用 Joanna Briggs 研究所批判性评估工具检查表评估研究质量,并通过推荐分级、评估、开发和评估(GRADE)评估确定性。终点包括主要通畅率、靶病变血运重建、支架断裂、次要通畅率和一年死亡。
共有 37 项研究(33 项队列研究、2 项病例系列研究和 2 项随机对照试验[RCT])被纳入荟萃分析,共涉及 4480 名参与者。其中,34 项研究的数据包含 Supera 支架(81.5%的参与者),3 项研究的数据包含 BioMimics 3D 支架(18.5%的参与者)。33 项研究在一年随访时的主要通畅率为 81.4%(95%置信区间[CI]78.7-83.9%),18 项研究在一年时的靶病变血运重建率为 12.2%(95%CI9.6-15.0%)。GRADE 评定的证据质量为低质量。只有一项研究报告了一年时 0.4%的支架断裂率,证据质量为低。
使用仿生支架治疗下肢 PAD 可能与可接受的一年主要通畅率和靶病变血运重建率相关,且一年时支架断裂率几乎可以忽略不计。对于接受血管内再血管化治疗的下肢 PAD 患者,应考虑使用仿生支架。需要进行 RCT 以确定其临床和成本效益。